Stepping through multiple hypoglycemic programs has achieved nothing, GLP-1RA hypoglycemic and kidney benefits are all effortless
Time of Update: 2022-02-23
*For medical professionals only for reference After adding GLP-1RA, the treatment plan was simplified, the blood sugar of the patients was better controlled, and the renal function indexes were improved .
The latest data of "nonnepterone" is released! Similar "heart-kidney benefit" in patients with comorbid obesity
Time of Update: 2022-10-02
Previous studies: Nonneptaride can bring heart and kidney benefits for type 2 diabetes Finrenone is a selective nonsteroidal mineralocorticoid receptor antagonist (MRA), and the FIDELITY study (pooled analysis of FIDELIO-DKD and FIGARO-DKD studies) suggests that finerione reduces cardiovascular (CV) and renal outcome risk in patients with type 2 diabetes and chronic kidney disease (CKD).
Lancet Diabetes Endocrinol: Patients with Severe Insulin Resistant Diabetes (SIRD) Benefit from
Time of Update: 2022-04-23
In chronic kidney disease (CKD) , researchers sought to study the association of the new classification with postoperative outcomes in two different groups of patients with type 2 diabetes and obesity who underwent bariatric surgery .
1+1>2, the combination of fenelrone + SGLT-2i will benefit the heart and kidney more
Time of Update: 2021-10-22
McGill’s report is based on the FIGARO-DKD trial, which is a randomized, double-blind, placebo-controlled, parallel-group, multi-center Phase 3 clinical study, with participants from 47 countries, combined with CKD 7437 adult patients with type 2 diabetes .
Diabetic combined kidney disease or heart failure patients benefited more from SGLT1/2 inhibitors
Time of Update: 2021-01-18
Screenshot Source: The New England Journal of MedicineSOLOIST trial assesses the risk of death from cardiovascular causes and re-hospitalization and emergency care due to type 2 diabetes and recent heart failure.
Advanced kidney cancer "immune and targeted" first-line treatment! BMS/ Exelixis combination
Time of Update: 2020-10-06
!-- Webeditor: page title-- September 21, 2020 // -- BMS and partner Exelixis recently unveiled the anti-PD-1 Therapy Opdivo (Odivo, generic name: nivolumab, navuliyu monoanti) combined to target the anti-cancer drug Cabometyx (cabozantinib, cabodinib) first-line treatment of advanced renal cell carcinoma (RCC) key Phase III CheckMate-9ER trial results.